Now that Blueprint Medicines Corp’s volume has hit 2.96 million, investors get a glimpse of its size.

On Tuesday, Blueprint Medicines Corp (NASDAQ: BPMC) was unchanged from the session before settling in for the closing price of $128.4. A 52-week range for BPMC has been $73.04 – $128.52.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Annual sales at Healthcare sector company grew by 31.87% over the past five years. When this article was written, the company’s average yearly earnings per share was at 34.48%. With a float of $62.27 million, this company’s outstanding shares have now reached $64.56 million.

Let’s look at the performance matrix of the company that is accounted for 649 employees. In terms of profitability, gross margin is 95.84%, operating margin of -31.01%, and the pretax margin is -27.38%.

Blueprint Medicines Corp (BPMC) Insider Updates

Also, it is sometimes useful to examine the sentiment of large-scale investors toward Blueprint Medicines Corp stocks. The insider ownership of Blueprint Medicines Corp is 3.71%, while institutional ownership is 106.61%. The most recent insider transaction that took place on Jul 03 ’25, was worth 150,309. In this transaction CHIEF OPERATING OFFICER of this company sold 1,172 shares at a rate of $128.25, taking the stock ownership to the 63,546 shares. Before that another transaction happened on Jul 03 ’25, when Company’s CHIEF SCIENTIFIC OFFICER sold 1,051 for $128.25, making the entire transaction worth $134,791. This insider now owns 53,155 shares in total.

Blueprint Medicines Corp (BPMC) Performance Highlights and Predictions

According to the Wall Street analysts, stocks earnings will be around 34.48% per share during the next fiscal year.

Blueprint Medicines Corp (NASDAQ: BPMC) Trading Performance Indicators

You can see what Blueprint Medicines Corp (BPMC) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.75. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 14.77.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.46, a number that is poised to hit -0.44 in the next quarter and is forecasted to reach 0.92 in one year’s time.

Technical Analysis of Blueprint Medicines Corp (BPMC)

Blueprint Medicines Corp (NASDAQ: BPMC) saw its 5-day average volume 2.23 million, a positive change from its year-to-date volume of 2.0 million. As of the previous 9 days, the stock’s Stochastic %D was 61.39%.

During the past 100 days, Blueprint Medicines Corp’s (BPMC) raw stochastic average was set at 99.32%, which indicates a significant increase from 51.28% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.27 in the past 14 days, which was lower than the 3.04 volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $113.27, while its 200-day Moving Average is $98.05. Nevertheless, the first resistance level for the watch stands at $128.68 in the near term. At $128.97, the stock is likely to face the second major resistance level. The third major resistance level sits at $129.16. If the price goes on to break the first support level at $128.21, it is likely to go to the next support level at $128.02. Assuming the price breaks the second support level, the third support level stands at $127.73.

Blueprint Medicines Corp (NASDAQ: BPMC) Key Stats

There are 64,582K outstanding shares of the company, which has a market capitalization of 8.30 billion. As of now, sales total 508,820 K while income totals -67,090 K. Its latest quarter income was 149,410 K while its last quarter net income were 500 K.

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.